SOUTH SAN FRANCISCO, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the fourth quarter of 2015 were $9.8 million, compared to $21.8 million, which included a $15 million milestone payment from Astellas, during the same period in 2014. The net loss for the fourth quarter was $9.2 million, or $0.24 per basic and diluted share. This is compared to net income for the same period in 2014 of $8.4 million, or $0.23 per basic share and diluted share. As of December 31, 2015, cash, cash equivalents and investments totaled $111.6 million.
